Potter, Danielle S.
Du, Ruochen
Bhola, Patrick
Bueno, Raphael
Letai, Anthony http://orcid.org/0000-0002-1993-9013
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35 CA242427)
Article History
Received: 5 May 2021
Revised: 13 May 2021
Accepted: 20 May 2021
First Online: 27 July 2021
Competing interests
: A.L. discloses consulting and sponsored research agreements with AbbVie, Novartis, and Astra-Zeneca. He is on the scientific advisory board of Flash Therapeutics, Dialectic Therapeutics, and Zentalis Therapeutics. The following are US Patents regarding BH3 profiling, owned by Dana-Farber: 10,393,733; 9,902,759; 9,856,303; 9,540,674; 8,221,966; 7,868,133. A.L. and P.B. are inventors on patent applications US20180128813A1, US20180120297A1 held/submitted by Dana-Farber Cancer Institute that covers HTDBP.
: Primary NSCLC tumors described in the manuscript were obtained after patients signed an informed consent approved by the Institutional Review Board (#98-063). All mice used in the manuscript were maintained within the DCFI animal facility and all experiments involving animals were conducted in accordance with the DFCI policy and animal protocol, reviewed and approved by the DFCI Institutional Animal Care and Use Committee.